NCT04985812View on ClinicalTrials.gov

A Study of JNJ-67484703 in Participants With Active Rheumatoid Arthritis

PHASE1CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

October 18, 2021

Primary Completion Date

May 18, 2023

Study Completion Date

May 18, 2023

Conditions
Rheumatoid Arthritis
Interventions
DRUG

JNJ-67484703

Participants will receive JNJ-67484703.

DRUG

Placebo

Participants will receive placebo to JNJ-67484703.

Trial Locations (11)

1023

Budai Irgalmasrendi Korhaz, Budapest

2000

ARENSIA Exploratory Medicine Unit, Kiev

2143

CRU Hungary Kft., Kistarcsa

3200

Clinexpert Kft, Gyöngyös

15006

Hosp Univ A Coruna, A Coruña

28040

Hosp. Clinico San Carlos, Madrid

28041

Hosp. Univ. 12 de Octubre, Madrid

36207

Pinnacle Research Group, LLC, Anniston

60467

GCSP/CIS Orland Park, Orland Park

0112

Arensia Exploratory Medicine, Tbilisi

MD-2025

Arensia Exploratory Medicine, Chisinau

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT04985812 - A Study of JNJ-67484703 in Participants With Active Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter